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Whether to use infant formula is a difficult question because it takes place against the backdrop of two big issues: breast feeding and AIDS. Breastfeeding activists fear that if Nestlé or Wyeth get a foot in the door of donating infant formula to women in poor countries, those firms will resume their wrongful marketing practices of the past and will target women who are HIV negative to cultivate a new market for formula. Very few women know their HIV status, which makes it impossible to direct the donation to those who could benefit from it.
The welfare of women and their babies is best protected by increasing international funding for AIDS care in poor countries. This would allow the manufacturers' donation to be deployed safely. Some of the aid money should be used to test pregnant women for their HIV status. For women who test negative, breast feeding should be promoted as usual. Women who test positive should be given nevirapine to block the transmission of HIV to the infant during labour (Boehringer-Ingelheim offers it for free). They should be given highly active antiviral treatment (HAART)-offered cheaply by many companies-to prolong their lives, so that the children will not become AIDS orphans. They should be given infant formula and receive education in how to use it safely (thereby taking up Nestlé's and Wyeth's offer). Such a plan maximises public health.
The dispute here is a tempest in a teapot created by impoverished healthcare budgets that make the above steps unaffordable. Nestlé, Wyeth, Unicef, and breastfeeding activists should approach the governments of the oil exporting countries as donors. These 22 governments could easily provide the $10bn annually that may be needed for this and other AIDS needs (their aggregate national income is $21trillion). Yet their aid for AIDS in Africa recently totalled only about $70m annually, or perhaps twice that at most. 2 Impoverished international aid makes for impoverished health systems and impoverished policy options that nobody agrees on. Changing this status quo, and demanding that wealthy governments fund AIDS care decently, would be far more productive than the conflict engaged in so far. 
Amir Attaran director

Atypical antipsychotics in the treatment of schizophrenia
Users' experiences of treatments must be considered
Editor-Geddes et al highlight the poor quality of research into antipsychotic drugs. 1 People who use these medicines, and their carers, would strongly echo these views. Yet the authors use these weak data, putting them through the sophisticated statistical technique of meta-regression analysis, to produce a didactic response: "conventional drugs should remain the first treatment." The analysis combines studies of six different atypical antipsychotics, including one (clozapine) that is seen by most clinicians as quite different, conducted over 21 years in several different countries. No examination of likely confounding effects is reported; insufficient figures were included in the paper to check. The team's draft report in July 1999, however, suggests that the correlation between effect difference and control dose of haloperidol may be an artefact of including the different atypical antipsychotics in a single analysis. This is bad science, and worse medicine. Geddes et al have identified important hypotheses: that the optimal dose of conventional antipsychotics may be lower than previously believed and that this dose range may give comparable average efficacy and tolerability to those of atypical antipsychotics. These hypotheses are worthy of study but are not shown by the method used.
Each antipsychotic has a different range of benefits and side effects, and these are of different importance to each user. Given the highly disabling effects of side effects on people's lives, users must have informed choice. They should also expect that their doctor is free to prescribe the best. If the person is too ill to discuss options and there are no other factors, current evidencerepeated by Geddes et al-points to atypical antipsychotics as the first choice.
The National Schizophrenia Fellowship, in partnership with Mind and the Manic Depression Fellowship, has published the largest ever survey of users' experiences of treatments. The results confirm the seriousness of the side effects, poor information about treatments, and denial of choice. Full data are available on www.nsf.org.uk/ information/research/ and are being submitted to the National Institute for Clinical Excellence for its technology appraisal of antipsychotics.
We urge clinicians to stop and think before accepting Geddes et al's results. It can be profoundly traumatic to be rendered rigid, trembling, unable to rest, or obese by drug treatment and still coming to terms with the diagnosis, the stigma, and the loss of hopes and expectations that the diagnosis carries.
Competing interests: The National Schizophrenia Fellowship has accepted grants and contracts from central and local government and the NHS; it has also accepted much smaller grants from pharmaceutical companies. Mind will not solicit or accept money from pharmaceutical companies but will participate in conferences that are funded by such companies. The Manic Depression Fellowship has received grants from central and local government and the NHS; it has also occasionally received small grants from pharmaceutical companies (less than 0.5% of its income in any one year) but not in the past two years.
Pragmatic considerations are important when considering which drug to prescribe
Editor-Geddes et al suggest that atypical antipsychotic drugs are no better tolerated than low dose typical antipsychotics and go on to recommend starting treatment with 6-12 mg/day haloperidol or equivalent.
1 It should not be assumed, however, that typical antipsychotics are anything like well tolerated at these doses. Acute extrapyramidal effects, hyperprolactinaemia, and tardive dyskinesia are frequent problems even at lower, essentially subtherapeutic, doses.
2 Of course, the last two of these develop some time after the standard six weeks of treatment used in trials. This, and the fact that withdrawals from trials are not a precise measure of patient acceptability, might explain why no clear difference in tolerability was discerned.
The authors also recommend using atypical antipsychotics when patients do not respond adequately to a standard dose of conventional antipsychotic. This is not evidence based. Only clozapine seems to be effective in patients unresponsive to previous treatment, with data relating to other atypical antipsychotics being at best equivocal. 3 Moreover, none of the data presented in the review seems to support the authors' recommendation.
Arguments surrounding the relative tolerability and efficacy of the different types of drugs are rendered largely redundant by more pragmatic considerations. Atypical antipsychotics are rarely prescribed alone in everyday practice, and concomitantly prescribed conventional antipsychotics greatly increase the frequency of acute movement disorders 4 and, presumably, worsen tolerability. 
David Taylor
Validity of dropout rates as proxy measure of tolerability is unknown
Editor-Geddes et al's analysis of atypical antipsychotic drugs contains sources of bias that they did not address. 1 Atypical antipsychotics are a heterogeneous group of drugs with important differences. The most transparent measure of atypicality is the degree to which adverse effects mediated by dopamine receptor blockade are reduced. 2 Thus generalisations that include all of the atypical antipsychotics introduce a bias that dilutes the benefits of the two most atypical compounds, clozapine and quetiapine.
Another source of bias in this paper is the use of dropout rates from clinical trials as the measure of tolerability. In many trials of antipsychotics the dropout rate is linked less with tolerability than with lack of efficacy; thus their use as a measure of tolerability is unreliable.
Geddes et al accept that atypical antipsychotics cause fewer extrapyramidal side effects, which are well known phenomena that add to morbidity and stigma in schizophrenia. But other, absolute measures of adverse effects mediated by dopamine receptor blockade are available.
An increase in plasma prolactin concentration is a serious adverse effect of antipsychotics and can be measured in absolute terms, but Geddes et al did not use it as a measure of tolerability. Modest doses of conventional antipsychotics rapidly increase plasma prolactin concentrations to abnormal levels, and symptomatic hyperprolactinaemia has been reported with conventional antipsychotics well below their effective therapeutic doses in schizophrenia. 3 In the comparison between quetiapine and chlorpromazine included in the analysis, a significant reduction in prolactin concentrations from baseline values was seen in patients treated with quetiapine but not in those treated with chlorpromazine. 4 In another study prolactin concentrations in patients treated with quetiapine were no different from those in patients treated with haloperidol or placebo and remained within the normal range even at the highest dose. 5 In contrast, plasma prolactin concentrations in patients treated with haloperidol at a dose of 12 mg/day increased to more than twice the highest level for patients treated with quetiapine (P = 0.0075) 5 and were in the range that in otherwise healthy women should prompt a search for a prolactinoma.
Geddes et al conclude that treatment with haloperidol at a dose of <12 mg/day will optimise both tolerability and effectiveness. However, it is difficult to have any confidence in their findings. The validity of dropout rates as a proxy measure of tolerability is unknown. Moreover, they do not correlate with objective measures of adverse effects and their use in this way cannot be considered to be evidence based. Although patients may experience distressing extrapyramidal side effects and their adverse impacts, doctors alone decide whether a patient's side effect is excessive and therefore what drug is to be used. Few patients are told of the risk of tardive dyskinesia, and patients with this irreversible condition do not even know it is drug related.
My experience with patient groups in Hong Kong shows that they are usually less concerned with treatment efficacy than are the authors of meta-analyses. What frighten them most are, in descending order of importance, social stigma, extrapyramidal side effects (themselves a cause of visible stigma), and relapse of the mental condition. There is a long way to go before the "informed relationship between doctor and patient" that Geddes et al alluded to will happen in many parts of the world. 
Users' views are important
Editor-Geddes et al's meta-analysis of atypical versus typical antipsychotics must be interpreted carefully. 1 The overall advantage of atypical compared with typical antipsychotics as used in current clinical practice should not be dismissed. It is extremely optimistic to imagine that doses of typical antipsychotics will be reduced in practice, given the difficulty in getting doctors to change prescribing-for example, to increase the dose of tricyclic antidepressants. 2 Even if lower doses of typical antipsychotics are used, the efficacy advantage for atypical antipsychotics is not necessarily abolished: the 95% confidence interval encompasses a clinically important advantage to atypical antipsychotics but only a small disadvantage. With regard to tolerability, I take issue with equating it to the number of dropouts due to all causes. This is a measure of several very different factors, comprising a mixture of protocol deviation, withdrawal of consent, stopping due to treatment failure or success, as well as adverse events. It is therefore sensible to analyse discontinuations attributed to adverse events alongside total dropouts; even then we are looking at only one aspect of tolerability, and using this measure alone will not detect the patients who continue with treatment despite appreciable side effects.
This analysis found that atypical antipsychotics cause fewer extrapyramidal side effects even than lower dose typical antipsychotics, and the strong clinical impression, supported by the accompanying editorial, 3 is that patients choose to avoid these side effects if they can. What is missing from the interpretation of this analysis is any acknowledgement that the users' view may be important. It is difficult therefore to accept the authors' conclusion that atypical antipsychotics are no better tolerated than typical antipsychotics; on the evidence given it just depends on what you mean.
Finally, and perhaps most importantly, the basis of the value judgment used to arrive at the conclusion that typical antipsychotics should be used as first line drugs is not explicit. It seems, despite the authors' protests, to be based implicitly on cost effectiveness by weighing a large cost difference against a perceived absent or minor clinical benefit. I have argued here about the uncertainty of the evidence; how much more uncertain is the translation to recommendation? My own interpretation is that we are condemned to continue living with the uncertainty about whether to use typical or atypical antipsychotics as first line treatment. Might this be a situation in which we should listen to our patients?
Cost is a crucial issue
Editor-The impressive meta-regression analysis by Geddes et al was disappointing in its sidestepping of current issues. 1 The authors believe that "cost is not a crucial issue at present" because most outcome scores for atypical antipsychotic drugs are the same as those for typical antipsychotics. Their predominant message is, however, that typical antipsychotics should be first line treatment. We strongly disagree that cost is not a crucial issue as it seems to be the only differentiator between the new and old antipsychotic drugs. If cost were not a crucial issue why would Geddes et al recommend which type of antipsychotic should be prescribed first?
As trainee psychiatrists, perhaps we have too much of what Kapur and Remington describe in their editorial as clinical hope, 2 but we do see a key first line role for atypical antipsychotics. We appreciate being flexible in working collaboratively with patients and able to discuss factors such as weight gain, akathisia, parkinsonism, sexual dysfunction, and risk of tardive dyskinesia. In being offered a choice of drug treatment our patients effectively have a choice about their potential side effects. Prescribing only typical antipsychotics would reduce this choice. The authors state that no single antipsychotic is to be favoured over another and we would like to have all treatment options available in our first line armoury.
We encourage Geddes et al to recognise that cost is a crucial issue and to realise that in effect they have presented a cost minimisation analysis. 
Richard Duggins senior house officer in psychiatry
Paper underrates patients' experience of extrapyramidal symptoms
Editor-Geddes et al studied 52 randomised trials of atypical antipsychotic drugs in the treatment of schizophrenia. 1 They conclude that there are a few differences in efficacy measures and overall tolerability of conventional versus atypical antipsychotics, the main difference being in the propensity for extrapyramidal symptoms. I don't think that there is anything new here; many of us who have followed the literature have come to this conclusion. I do think, however, that the paper underrates patients' experience of extrapyramidal symptoms. It is precisely because of patients' experience of these symptoms-not for the relatively unproved superior efficacy-that patients, carers, and charitable groups have campaigned for wider use of atypical antipsychotics. Kapur and Remington's accompanying editorial rightly states that data pooling misses important and proved niche effects, 2 such as the superiority of clozapine in patients with refractory disease. 3 A further missed point is that apart from clozapine there is no evidence for a role of atypical antipsychotics in schizophrenia resistant to treatment. 4 Thus the suggestion that atypical antipsychotics should be reserved for patients in whom treatment with conventional drugs has failed seems spurious. In reality, most of our prevalent group of patients are already taking conventional drugs. Therefore most episodes of schizophrenia should probably be treated anyway with atypical antipsychotics according to the guidelines.
As with all guidelines, one should really focus on the first episode of the disease, as there will be many disease modifying factors that will influence drug response. Nothing in this paper informs practice here. Virtually all 52 trials studied were registration trials in patients with multiple episodes or chronic disease. What evidence there is for the first episode strongly suggests that it is exquisitively sensitive to extrapyramidal symptoms and that atypical antipsychotics may be superior to low dose haloperidol. 5 Therefore, on the basis of current data, atypical antipsychotics seem to be the drugs of choice at first presentation.
Finally, the authors use the dropout rate as a surrogate for overall tolerability. What is the evidence for this? This is not an unfair question to ask in such an evidence based exercise. My experience of clinical trials in schizophrenia is that patients often drop out because they are deluded, hallucinated, disorganised, and unable to maintain consent. It is premature to conclude that this paper gives support to reversing the trend for wider use of atypical drugs.
Paper corrupts concept of evidence based medicine
Editor-The BMJ champions evidence based medicine, 1 but Geddes et al's review of atypical antipsychotics in the treatment of schizophrenia 2 leaves clinicians "on a tightrope act between the persuasiveness of marketing claims, the precise but somewhat myopic results of idealised clinical trials, and the complex realities of clinical practice.'' 3 The reviewers report results of metaregression, a hypothesis generating technique by which observational epidemiological techniques are applied to trials. They then state, as if hypotheses had been tested, that "conventional antipsychotics should usually be used in the initial treatment of an episode of schizophrenia unless the patient has previously not responded to these drugs or has unacceptable extrapyramidal side effects." 2 This statement ignores basic epidemiological principles.
Was the study the strongest that could have been performed? No. Only a subset of atypical drugs is studied, 4 and these data are out of date; the 1988 search is supplemented by inclusion of data on one study available only in 1999, yet other trials available by that time were ignored. 5 Only continuous, composite measures of effect on mental state were used. The tables in the paper state that 32% of people left these studies early, and in such trials people who leave early are often assumed to remain stable from their point of exit. Therefore, one third of the data in the meta-analyses, the basis of the metaregression, probably carry this unlikely assumption.
Did the review assure readers that it minimised the inclusion of bias? No. Exactly how studies were selected, outcomes chosen, and data extracted and entered and analysed is not explained. As consistently more people allocated to typical antipsychotics leave studies early, the assumption of stability beyond the point of exit favours haloperidol and chlorpromazine.
Was the strength of the association, both clinical and statistical, considered? No. Clinical importance was hardly considered, and the reproducibility of results, using different end points, and the effect of controlling for the inevitable confounding were not discussed.
Geddes et al's study could alienate clinicians from practical gains evident from open, well conducted systematic reviews. Smith's editorial stated that it is a lie to suggest that "which interventions to make available can be decided with some data and a computer" and that this "corrupts the concept of evidence based medicine.'' 1 We are concerned that Geddes et al's work, disseminated through the BMJ, the champion of evidence based medicine, corrupts the concept of evidence based medicine and could harm people with schizophrenia. Competing interests: CEA has attended, and presented information at, functions sponsored by Janssen-Cilag and Eli Lilly. These companies have provided travel, accommodation, and speaker's expenses, but no funds have been paid directly to CEA. Payments related to participation in meetings have been paid to an account to support schizophrenia research. LD has attended functions sponsored by Lundbeck, Janssen, Novartis, Pfizer, and Zeneca and has accepted sponsorship from Eli Lilly for internal flights in the United States and from Janssen for talks. The Cochrane Schizophrenia Group has multiple, and hopefully balancing competing interests. Potential competing interests of the group and individuals are described on http://cebmh.warne.ox.ac.uk/csg/ and sources and quantities of all funding listed. 
Authors' reply
Editor-Despite the time that has elapsed since we completed our review, none of the correspondents challenges our findings with new randomised evidence. The disagreements concern our methodology and conclusions.
We agree with several authors that the current randomised evidence is inadequate, but it is important that decisions are based on the best available (albeit imperfect) randomised evidence rather than opinion or selective citation of individual trials. We emphasised the importance of integrating the evidence we presented with clinical judgment and patient preference.
Existing trials have usually been conducted by drug companies for regulatory purposes and have excluded or underrepresented clinically important subgroups of patients such as elderly people and those at an early stage of the illness. It is certainly possible, as Kerwin says, that differences exist between subgroups of patients; rather than missing these, meta-regression can be a powerful way of detecting them. 1 We disagree with both Taylor and Kerwin about the role of atypical antipsychotic drugs in patients who have not responded to treatment with conventional antipsychotics. This is one subgroup that was well represented in the trials because many of the trial participants had had a suboptimal response to conventional antipsychotics. Definitions of resistance to treatment have broadened since the landmark clozapine study, 2 and the most clinically useful approach is to consider a change of treatment in any patient in whom response or tolerability is suboptimal. 3 From a clinical perspective, we consider that it is reasonable to use an atypical antipsychotic if results with one (or more) conventional antipsychotics have been unsatisfactory.
Meta-regression is an established technique for addressing heterogeneity (systematic differences) in the results of randomised trials. 4 Exploring heterogeneity according to protocol driven criteria makes appropriate use of the available evidence. 5 Our analysis not only showed the effect of dose on continuous symptom measures with haloperidol but also replicated the finding both for dropout and for the group of trials using chlorpromazine as the comparator. These analyses provide strong evidence for the importance of dose of typical antipsychotic, and are supported by the analyses in which doses were simply dichotomised.
Since higher doses of conventional drugs lead to an increased probability that patients will abandon treatment in trials it is not surprising to find that those same patients have poorer outcomes-the two factors are inextricably linked. In most of the studies, when patients withdrew from the allocated treatment they were considered to have dropped out of the trial.
"Dropout" is a composite outcome including elements of both efficacy and tolerability, but because of the poor reporting of specific adverse events in the studies we reviewed we considered it to be the least biased estimate of the overall acceptability of a treatment. The "last observation carried forward" method was widely used to deal with the resulting missing data to allow an intention to treat analysis. As patients taking typical antipsychotics dropped out earlier on average, this approach will tend to overestimate the comparative efficacy of the atypical drug, because patients leaving the study early will tend to have more symptoms, in contrast to the statement of Adams and Duggan.
Rather than ignoring clinical significance, our work was located firmly in the clinical practice of a group of concerned and interested clinicians and was extensively peer reviewed before submission to the BMJ. Adams and Duggan suggest that our review could harm people with schizophrenia, but they do not state how this might happen or how their interpretation of the data differs from ours.
Kerwin considers that we understated the burden of extrapyramidal side effects, while Prior et al imply that we suggested patients should "be rendered rigid, trembling, unable to rest, or obese by drug treatment." In fact, we stated that no patient should have to tolerate extrapyramidal side effects, as has all too often been the case. Unfortunately, the benefits on extrapyramidal side effects achieved by atypical antipsychotics are relatively modest and should be considered in the context of the similar overall dropout rates which, despite the caveats mentioned above, show at the very least that the atypical antipsychotics are not unequivocally more tolerable.
Our view remains that the available randomised evidence does not support a wholesale change from conventional drugs as standard first line treatment. It is the gaps in the evidence rather than the cost that should lead clinicians to consider conventional drugs first, though we accept that in many cases a patient's preference or clinician's judgment may make the first line use of atypicals appropriate. Many of the correspondents' criticisms seem to be based on citation of individual trials or secondary outcomes, or to stem from an implicit belief that the burden of proof is on the established drugs, not the new ones, to show superiority. A serious consequence of a premature or uncritical shift to atypical antipsychotics is that it would be difficult to conduct the randomised trials required to answer the many outstanding questions (the existence of which is agreed by all correspondents) because clinicians and patients will not participate. for Evidence Based Mental Health, has run workshops around the United Kingdom, organised independently, but often sponsored by pharmaceutical companies. The centre has therefore indirectly received fees and expenses from several of the companies that manufacture antipsychotic drugs. NF has received funds for research, fees, and expenses from several pharmaceutical companies that manufacture antipsychotic drugs and from the Department of Health in England. PH has received support from pharmaceutical companies to attend conferences. He has also received fees for educational lectures to psychiatrists on the psychopharmacology of schizophrenia. PB has received fees for presentations at meetings sponsored by various pharmaceutical companies that manufacture typical and atypical antipsychotics. In addition, he is one of the lead investigators of the European schizophrenia cohort funded by Lundbeck. 
Psychological debriefing
Providing good clinical care means listening to women's concerns
Editor-Small et al have shown the ineffectiveness of debriefing in reducing maternal depression after operative childbirth. 1 Although we agree with the general findings of their study 2 some methodological issues must be addressed, especially if their findings are interpreted to mean that women should not have the opportunity to talk about their delivery experiences in a therapeutic and supportive manner.
The authors assert that the expected prevalence of postnatal depression is 24% 3 ; this is considerably higher than the 13% reported in other studies. 4 They assessed postnatal depression using the Edinburgh postnatal depression scale at six months postpartum (when its validity is uncertain), thereby excluding women who had had postnatal depression earlier but then recovered.
Additionally, there is no indication in this study of the degree of stress associated with the delivery, and elective and emergency procedures were aggregated. In our clinical experience a forceps delivery is more traumatic than an elective caesarean section.
Although a good response rate was achieved on the 1041 postal questionnaires, 662 eligible women did not participate (275 women declined to participate and participation was declined by the woman's doctor for 387 women), and 710 eligible women were discharged too soon to complete the study; therefore, less than half of all eligible participants actually entered the study. This calls into question the representativeness of the sample.
Little detail is provided about the debriefing. Lee et al have highlighted the desirability of a debriefing after miscarriage being conducted by someone who could provide factual information and answer questions about the event. 5 The research midwives would not have been present at the delivery and may not have been able to address specific issues raised by the participants. Furthermore, in their views of postpartum care the women who had been debriefed did not differ from the women who had had standard care (information from table on the BMJ's website available at www.bmj.com/cgi/content/full/321/7268/ 1043/DC1). This could mean that all women received fundamentally good clinical care or that the debriefing was not sufficiently useful.
Debriefing is aimed at preventing posttraumatic stress disorder, not depression. It is questionable whether a single session of debriefing would have an impact on the onset of postnatal depression when other psychosocial variables contribute more to its onset.
While we agree with the general thrust of this paper, which shows the ineffectiveness of debriefing, it is important to remember that after undergoing a traumatic delivery women should be provided with good clinical care which includes the opportunity to talk about their experiences of delivery. 
Philip Boyce professor of psychiatry
Research methodology was inadequate
Editor-The paper by Small et al and the editorial by Kenardy highlight two important issues that have contributed to the continuing confusion and controversy over the effectiveness of psychological debriefing. 1 2 Firstly, debriefing has been used as an umbrella term to describe a range of different interventions. While Kenardy acknowledges the importance of defining the debriefing intervention that is provided, the specific model, structure, and process used by Small et al is unclear. Psychological debriefing is a systematic process that explores in-depth a person's experience, cognition, attributions of an event, and the emotional reactions that arise from it as well as providing information about common reactions and coping strategies. 3 4 Talking about an experience, listening with empathy, and facilitating understanding of typical reactions are important but in themselves are not debriefing.
Secondly, research in this area is extremely limited and is plagued by methodological inadequacies; additionally, all of the handful of studies that have been reported have been with adults. No randomised controlled trials have been undertaken with children, and yet it has been suggested that such an intervention could be useful. 5 To universally dismiss psychological debriefing as potentially harmful is to draw a simplistic conclusion that is far outweighed by the evidence. A more sophisticated and methodologically robust approach is required to explore issues such as whether debriefing is effective with certain groups and whether the timing, length, and specific content of the intervention are important determinants of effectiveness. 
Paul Stallard consultant clinical psychologist
Qualitative research may be more appropriate
Editor-The paper by Small et al addresses an important area in postnatal care: that of treating maternal depression after operative childbirth. 1 It is an area that is likely to become more significant given the increasing rates of caesarean section in the United Kingdom. 2 Leaving aside the issue of what constitutes debriefing, there is a fundamental question to be asked of Small et al's study: was a randomised controlled trial the most appropriate choice to assess the intervention?
Although randomised controlled trials have a number of advantages, 3 they may not be appropriate when assessing interventions in which an impact is poorly understood. In particular they lead to estimates of effects in aggregate. Thus randomised controlled trials are not able to detect beneficial or adverse effects that happen selectively to as yet undefined subgroups within the population studied. 4 In this study it seems plausible that some individuals may be helped and some may be damaged by postnatal debriefing. Yet without prior specification of the defining characteristics of these groups, any estimate of an average effect is unhelpful.
The important questions raised by this study (for example, what is the role of debriefing in preventing postnatal depression? Which women would benefit most from postnatal debriefing? Which women should avoid postnatal debriefing and what alternative methods of support might be more appropriate?) could better be addressed by in-depth qualitative research, which is better able to tease out the contextual factors that have an impact on this type of intervention. 3 5 Well designed randomised controlled trials based on a refined understanding of both debriefing and contextual factors might then be more helpful. 
Authors' reply
Editor-Should we have studied only women who had "stressful" births or only those who had emergency caesarean sections or difficult forceps births? Our study was a pragmatic trial designed to test the effectiveness of an intervention (debriefing by midwives), already in widespread use in the United Kingdom, in reducing raised rates of maternal depression found in previous empirical research to occur after operative births. Three statewide surveys conducted in Victoria from 1989 to 2000 found no significant differences in the prevalence of depression six to nine months postpartum between women who had had a birth involving elective or emergency caesarean section or forceps or vacuum extraction (S Brown, unpublished data).
1-3
The instrument we used to measure depression (the Edinburgh postnatal depression scale) has been used extensively into the second year after birth to measure probable maternal depression; we used this scale in our trial not to make a psychiatric diagnosis but to compare the intervention and control groups. We agree with Boyce and Condon that the term "postnatal depression" is problematic: a third of women with depression in an earlier study of ours rejected the term. 4 The participants in this trial were broadly representative of healthy women who had operative births at term in Victoria. Compared with the group of all women giving birth, there were fewer women who were younger than 25 years and more who were older than 34; more were primiparous; fewer were single and more were in relationships; more were in the highest income bracket and had higher levels of education. Doctors who declined participation on behalf of their patients did so for all their patients rather than selectively.
There were no significant differences between the trial groups in seeking help from others: from general practitioners, maternal and child health nurses, psychiatrists or psychologists, or a self help group for postnatal depression.
We support the need for more trials to test the effectiveness of debriefing; to explore which groups might benefit; and to determine the importance of timing, the length of the session, and the content.
We fully agree that all women deserve compassionate, kind, and competent clinical care during and after childbirth; when women seek opportunities to talk about their experiences of the birth it is critical that someone has the time and the skills for listening.
Rhonda Small research fellow
Judith Lumley professor Centre for the Study of Mothers' and Children's Health, School of Public Health, La Trobe University, 251 Faraday Street, Carlton, Victoria 3053, Australia
Hands off technique has many benefits for breastfeeding mothers
Editor-Kmietowicz's news article about promoting the initiation of breast feeding points to static breastfeeding rates over the past 20 years.
1 Support may, however, be just as important as promotion. Targeting specific groups to encourage them to breast feed is only part of the task. At present, women who already want to breast feed stop sooner than they had planned to, often because of setbacks or misunderstandings that can be avoided, or quickly corrected, with the right information and support. More than 80% of women who stop breast feeding before four months would have liked to have continued for longer. 2 Little research has been done into the finer points of how new mothers initiate breast feeding, but recent work has shown it could make a real difference between trying to breast feed and breast feeding. At the Royal Women's Hospital in Australia, which is accredited as baby friendly, the "hands off " technique has been implemented. 3 4 Midwifery staff have been taught to teach mothers about effective positioning and attachment with this programme, so the mothers learn to do it for themselves from the very beginning. Fletcher and Harris acknowledge that it is a challenge to alter midwifery culture, but that it is worthwhile and has brought benefits for mothers and babies, and for staff (increased professionalism and reduced back injuries). There are occasions when hands on is more appropriate, but Fletcher and Harris are now convinced that they are in the minority. 4 A recent survey of infant feeding across one county in the United Kingdom showed that, of 95 first time mothers who had decided fully to breast feed, only 46% were still fully breast feeding at around six weeks. 5 Those who had put their own babies to the breast for the first feed (hands off) were more likely to still be breast feeding (71%) than those who had someone else put the baby on for them (38%). But as only about one third of the new mothers put their own babies to the breast for the first feed, further research is needed to check whether the differences are statistically significant.
In the United Kingdom as a whole, most mothers are no longer giving any breast milk by six weeks. 2 It is likely that only a minority of mothers are getting positive breastfeeding experiences in this country. This needs to be addressed before more women are encouraged to try breast feeding. 
Partnership between NHS and pharmaceutical sector is needed
Editor-Smith's news item reported my concerns on the declining status of the NHS as a location for clinical trials conducted by pharmaceutical companies, and was clear and accurate. 1 Smith drew on material compiled by the research and development directorate of the NHS Executive, and I welcome their recognition of industry's issues and concerns. Moreover, I applaud the focus of the Clinical Research Working Group of the Pharmaceutical Industry Competitiveness Task Force, a joint initiative of government and industry that is seeking solutions for these problems, such that the NHS can become more attractive as the testing ground for innovative health care.
My reported comments should be viewed as a lament rather than a threat. Our British heritage is important for SmithKline Beecham [now GlaxoSmithKline] and we want the United Kingdom to be a world leader in clinical research. We hope that we can look forward to growing our research commitment in the country, particularly clinical trials in the NHS. I share the sentiment expressed in the NHS Plan, that the NHS has a major part to play in ensuring that the country remains an attractive base for the pharmaceutical industry.
The strategic value of the NHS to research and development in the pharmaceutical sector transcends organisational issues of clinical trials. We also look to the NHS to act as an informed and innovative customer, appreciating the social and economic value of new medicines. One opportunity that I raised at the London meeting, which elicited interest by all the constituencies present but was not covered in Smith's report, was the potential of the NHS population as a whole to serve as a research resource in health informatics. The NHS has pioneered the development of databases for patient care, audit, and, increasingly, research (for example the general practice research database and the Scottish health informatics and statistics division initiative), but the participation of the industry is now needed to make the most of the research promise.
There are challenges to face in terms of building informatics capacity and in addressing consent, confidentiality, and anonymisation issues, but there is enormous value in sharing data and analytical tools. The importance of public private partnership for SmithKline Beecham, to generate unrestricted data in biomedical research, has been shown by our participation in the Single Nucleotide Polymorphism Consortium and, most recently, the Mouse Genome Sequencing Consortium. The NHS occupies a singular position worldwide in its potential to function as a shared resource if research is recognised as a core activity for an NHS that has overcome its fear of innovation. Although their review covered 85 issues published by the six general medical journals from the beginning of the NATO bombing on 24 March 1999 to the end of July 1999 (nearly eight weeks after the cessation of bombing), the crisis in Kosovo began much earlier and the effects continue to this day. Their review stopped short at the end of July 1999, as it resulted in an incomplete accounting of articles published on this important topic and an erroneous conclusion that these journals are not publishing more substantial publications on the social determinants of health. For example, if the 19 week review by Neglia and Rochon had been extended by just one week, the issue of the Journal of the American Medical Association (JAMA) of 4 August 1999 would have been included, which contained five articles on the effects of the wars in either Bosnia or Kosovo (one original contribution, one editorial, two medical news stories, and a research letter). 2 In the issue of 2 August 2000, JAMA published two of the first major studies on the mental health and social functioning of Kosovar Albanians and the Serbian minority in Kosovo, along with another editorial on the health effects of the war in Kosovo. 3 It is notable, not disconcerting, that 23 of the 85 journal issues reviewed contained mention of the then current Kosovo crisis, and not surprising that most of the articles were news articles. During that time, Kosovo was news, and the completion, analysis, and publication of research takes longer than the reporting of news. Medical journals have not, as Neglia and Rochon conclude, marginalised war or ignored its role as a social determinant of health. Since 1975, medical journals have steadily devoted increased numbers of their pages to topics related to human rights, which include the effects of war and civil conflict and other social determinants of health, with more than 9000 such articles indexed in Medline between 1995 and 1999. 4 Every year since 1983 JAMA has dedicated the entire first issue each August largely to the effects of war, violence, and violations of human rights. Recognising their social and professional responsibilities, editors of many other medical journals also have devoted entire issues or regular columns to these important subjects.
Is general practice losing its way?
The job needs to be split in two Editor-In response to the article by Samuel I agree with many of his sentiments. 1 But I think that it is general practitioners who have lost their way, and not general practice. General practice now seems to be called primary care. It has undergone huge changes over the past 10-15 years and continues to change at a rapid pace. Patient care has, however, not got any better. The reason for this is that most of the changes in general practice so far have been around structure, process, and management.
Many of the forthcoming changes could have benefits for patient care, but general practitioners must decide which way they want to go. It is only right and proper that general practitioners should participate in the decision making process that is providing the current changes, but I do not believe that they can continue to be general practitioners and managers at the same time. General practitioners must decide whether they want to practice medicine-which is probably why we all entered the profession in the first place-or whether they want to manage the changes that are happening. It is not possible to do both at the same time.
My plea to general practitioners is to decide which route to take-do not try to do both jobs and leave patients waiting for routine appointments. In my own practice no patient has to wait longer than 24 hours to see a doctor, let alone a healthcare professional. Most of my patients can be seen on the same day. This is achieved through the flexibility mentioned by Samuel in his article. Patients' needs should be put first
Editor-Samuel shows how general practice has lost its way. 1 Although general practitioners are working their fingers to the bone and finding their work stresses difficult to cope with, patients who want to see them at short notice cannot obtain an appointment to do so. Patients yet again find themselves powerless while general practitioners have no doubt that they are running their practice in the correct way.
The two week wait occurs because general practitioners are busy screening and searching for "diseases" that can be treated, only sometimes for the benefit of the patient. When a patient eventually does find himself in the consulting room, his presenting complaint is often considered but fleetingly. He is then, however, subjected to a host of inquiries about his private life. He did not come for this, but, powerless in the doctor's lair, he has little option but to submit. Further tests follow, and then come the belittling homilies about eating, drinking, smoking, exercising, working, etc. The patients know all this, of course, and are only too conscious of their shortcomings. They do not want to be reminded of these, nor do they want to be made into a patient with all the downside that goes with this life situation. They do want their own individual health needs met. That is after all what they pay all that income tax for.
Who is general practice for? At present many practices, as Samuel describes, are run for the convenience of the practitioners, who are convinced they know best. This is no doubt an effect of having a capitated service. Were the doctor to receive a fee for servicing the patient's needs, rather than general practice's perception of these needs, patients would come first. Jones reported on walk-in centres, which were largely disapproved of. 2 They would, however, answer a lot of these problems. This would leave general practice to investigate the worried well and find some medical conditions to give some respectability to their worries. It really is time that patients' needs were put ahead of those of the bureaucratic surgery staff and their contracted practitioner. 
Study of walk-in centres was flawed
Editor-Jones in her news item reported a study that the Consumers' Association had conducted on NHS walk-in centres. 1 The title of the report implies conclusive results. Jones does not, however, mention the methodological flaws of the study, and there are many.
This was a small study, designed and presented in a similar fashion to that on NHS Direct, published in August last year, which attracted criticism. 2 Once again no control group was used, so we have no idea whether these "patients" would have fared any better if they had seen their own general practitioners or a general practitioner's deputising service or attended an accident and emergency department. Much is made in the paper about how patients were quizzed openly by reception staff at walk-in centres, and that "Bob," the potential emergency patient, did not get past reception in five centres, although he needed a proper consultation. Bob reportedly attended the centres asking for a repeat prescription for a glyceryl trinitrate spray for his angina. Is this indicative to a receptionist that he needed a proper consultation? We suspect that, had he gone to his own general practitioner and asked reception staff for a repeat prescription, he would have got one, probably a day or two later, but that he would not have received a consultation with a general practitioner unless he had asked for one. We do not know what he asked for at any of the walk in centres visited as no details of the script-if one was used-were included. This is not the only flaw in the article. We are told that scenarios were judged by a panel of experts, but we were not told of any instances in which they disagreed or had to reach a consensus. We do not believe that the panel agreed totally on each and every point mentioned in this paper. Altogether the weaknesses of the study make it unlikely that it would have been published in a peer reviewed journal. The business of the Consumers' Association is selling magazines to the public, and a certain amount of journalistic licence is to be expected. Whatever one's personal views on walk-in centres, however, the results of a properly designed evaluation such as that commissioned by the Department of Health should be awaited before passing judgment. Apples and oranges have previously been shown to be remarkably similar
Steve George reader in public health
Editor-Barone's short randomised prospective study comparing apples and oranges is a fresh example of a scientist unknowingly rediscovering something that has been reported previously. 1 In this case, the earlier investigation was done with more depth, more rigour, and, most importantly, more expensive equipment. The Annals of Improbable Research published Sandford's report comparing apples and oranges in 1995. 2 Sandford did a spectrographic analysis of ground, dessicated samples of a Granny Smith apple and a Sunkist navel orange.
The dried samples were mixed with potassium bromide and ground in a small ballbearing mill for two minutes. Samples (100 mg) of each of the resulting powders were then pressed into a circular pellet, having a diameter of 1 cm and a thickness of approximately 1 mm. Spectra were taken at a resolution of 1 cm -1 with a Nicolet 740 FTIR (Fourier transform infrared) spectrometer. The figure shows the 4000-400 cm -1 (2.5-25 mm) infrared transmission spectra of the two fruits.
Sandford thus showed not only that apples and oranges can be compared but also that they are remarkably similar. 
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